To include your compound in the COVID-19 Resource Center, submit it here.

ArQule grants Roivant rights to derazantinib in China and Taiwan

ArQule Inc. (NASDAQ:ARQL) granted Roivant Sciences GmbH (Basel, Switzerland) exclusive

Read the full 108 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE